Exelixis | EXEL - DÍVIDA





DÍVIDA Alterar Data
Acadia Pharmaceuticals USD 73.85M 23.06M 2026-06
Agios Pharmaceuticals USD 31.17M 4.57M 2026-06
Akebia Therapeutics USD 46.51M 7.82M 2025-03
Amgen USD 57.3B 19M 2026-06
AstraZeneca USD 32.24B 1.68B 2026-06
Bayer EUR 36.45B 2.93B 2025-12
BioMarin Pharmaceutical USD 4.19B 11.99M 2026-09
Bristol-Myers Squibb USD 42.88B 2.18B 2026-09
Cytokinetics USD 1.27B 18.17M 2026-06
Eisai JPY 186.08B 50.58B 2026-03
Eli Lilly USD 54.91B 11.54B 2026-06
Exelixis USD 162.2M 3.73M 2026-09
Genmab DKK 5.35B 5.2B 2026-03
Glaxosmithkline GBP 23.7B 4.65B 2026-09
Incyte USD 38.27M 1.16M 2026-06
Ionis Pharmaceuticals USD 1.77B 141M 2026-09
MacroGenics USD 35.09M 1.42M 2026-06
Merck USD 53.91B 4.79B 2026-06
Moderna USD 1.29B 11M 2026-06
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 392.3M 9.5M 2026-09
Novartis USD 49.01B 2.02B 2026-06
Pfizer USD 62.67B 523M 2026-09
Puma Biotechnology USD 89.06M 55.07M 2024-06
Sanofi EUR 23.58B 3.56B 2026-06
Takeda JPY 4.58T 364.32B 2026-09
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Xencor USD 170.11M 5.06M 2026-06